SCHEMBL7148404

SCHEMBL7148404

CCOC(=O)[C@@H](Nc1ccc(C(=N)NO)cc1)c1cc(OCC)c(OCCO)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 6/20 0.40
F10 P00742 6/20 0.40
PRSS1 P07477 4/20 0.40
F2 P00734 4/20 0.40
F3 P13726 4/20 0.39
PRSS2 P07478 2/20 0.39
PRSS3 P35030 2/20 0.39
KMT2A Q03164 3/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 1/20 0.35
RET P07949 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
BCL9 O00512 1/20 0.34
CTNNB1 P35222 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144190 1.00 F7 (0.40) F7F10PRSS1F2F3
SCHEMBL7144200 1.00 F7 (0.40) F7F10PRSS1F2F3
SCHEMBL7142864 0.93 F7 (0.38) F7F10PRSS1F2F3
SCHEMBL7148670 0.93 F7 (0.38) F7F10PRSS1F2F3
SCHEMBL7148598 0.93 F7 (0.38) F7F10PRSS1F2F3
SCHEMBL7142761 0.93 F7 (0.38) F7F10PRSS1F2F3
SCHEMBL7140099 0.93 F7 (0.38) F7F10PRSS1F2F3
SCHEMBL7145460 0.93 F7 (0.38) F7F10PRSS1F2F3
SCHEMBL7142757 0.93 F7 (0.38) F7F10PRSS1F2F3
SCHEMBL7147399 0.93 F7 (0.38) F7F10PRSS1F2F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548694-B2 Anticoagulants HOFFMAN-LA ROCHE INC. 2003-04-15 US claimed
EP-1289939-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-03-12 EP claimed
US-20020004608-A1 N-(4-carbamimidoyl-phenyl)-glycine derivatives F.HOFFMANN-LA ROCHE AG (CH) 2002-01-10 US claimed
WO-2001090051-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 WO claimed
US-6548694-B2 Anticoagulants HOFFMAN-LA ROCHE INC. 2003-04-15 US disclosed
EP-1289939-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-03-12 EP disclosed
US-20020004608-A1 N-(4-carbamimidoyl-phenyl)-glycine derivatives F.HOFFMANN-LA ROCHE AG (CH) 2002-01-10 US disclosed
WO-2001090051-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020004608-A1 N-(4-carbamimidoyl-phenyl)-glycine derivatives GLS, SLC6A5, GLRA1 F7 422/4885F10 546/4885PRSS1 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.